Literature DB >> 16525684

TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer.

Tatiana I Rogounovitch1, Vladimir A Saenko, Kiyoto Ashizawa, Ilya A Sedliarou, Hiroyuki Namba, Aleksandr Yu Abrosimov, Eugeny F Lushnikov, Pavel O Roumiantsev, Marina V Konova, Natalia S Petoukhova, Irina V Tchebotareva, Viktor K Ivanov, Sergei Yu Chekin, Tatiana I Bogdanova, Mykola D Tronko, Anatoly F Tsyb, Gerry A Thomas, Shunichi Yamashita.   

Abstract

The study investigated an association between the germline polymorphism at TP53 codon 72 and the development of papillary thyroid cancer (PTC) following exposure to radiation from the Chernobyl accident. TP53 genotype was examined in 48 pediatric/adolescent (age at diagnosis <18 years) and 68 adult post-Chernobyl patient with PTC, 53 adult patients with sporadic PTC and 313 healthy individuals from Russian-Ukrainian population. In addition, we evaluated loss of heterozygosity for TP53 and the allele expression ratio. The genotype of the patients was correlated with clinicopathological data. Arg TP53 homozygotes were found to be significantly underrepresented among adults with post-Chernobyl PTC, but not in children and adolescents when compared with sporadic PTC cases and the general population. In the tumors, cell transformation did not lead to allelic loss or biased TP53 allele expression in heterozygous individuals. None of TP53 genotypes specifically associated with tumor stage and morphology, however there were particular correlations with lymph node status in certain age groups of radiation-associated cases not seen in sporadic PTCs. The findings suggest TP53 allele combinations other than Arg/Arg may contribute to the risk of development of PTC in individuals exposed to radiation during their late childhood, adolescence or in young adulthood.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525684

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk.

Authors:  Fang Wang; Peng Wang; Bin Wang; Zheng-Ju Fu; Ying Yuan; Sheng-Li Yan; Wen-Juan Zhao; Yan-Gang Wang
Journal:  Tumour Biol       Date:  2013-12-28

2.  Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.

Authors:  Bo Wu; Dan Guo; Ying Guo
Journal:  Tumour Biol       Date:  2013-09-15

3.  Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis.

Authors:  Santhi Latha Pandrangi; Sarangadhara Appala Raju Bagadi; Navin Kumar Sinha; Manoj Kumar; Rima Dada; Meena Lakhanpal; Abha Soni; Shreshtha Malvia; Sheeba Simon; Chintamani Chintamani; Ravindar Singh Mohil; Dinesh Bhatnagar; Sunita Saxena
Journal:  Cancer Cell Int       Date:  2014-02-05       Impact factor: 5.722

4.  Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population.

Authors:  Naseem Akhter; Sajad A Dar; Shilpi Chattopadhyay; Shafiul Haque; Razique Anwer; Mohd Wahid; Arshad Jawed; Mohtashim Lohani; Raju K Mandal; N K Shukla; Yasir Abdul; Syed Akhtar Husain
Journal:  Curr Genomics       Date:  2018-08       Impact factor: 2.236

Review 5.  Genetic Polymorphism Predisposing to Differentiated Thyroid Cancer: A Review of Major Findings of the Genome-Wide Association Studies.

Authors:  Vladimir A Saenko; Tatiana I Rogounovitch
Journal:  Endocrinol Metab (Seoul)       Date:  2018-06

6.  Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers.

Authors:  V Detours; L Delys; F Libert; D Weiss Solís; T Bogdanova; J E Dumont; B Franc; G Thomas; C Maenhaut
Journal:  Br J Cancer       Date:  2007-08-21       Impact factor: 7.640

7.  Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study.

Authors:  Peng Chen; Ruifen Sun; Yan Pu; Peng Bai; Fang Yuan; Yundan Liang; Bin Zhou; Yanyun Wang; Yinghe Sun; Jingqiang Zhu; Lin Zhang; Linbo Gao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.